The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 1.84
Ask: 1.96
Change: -0.14 (-6.86%)
Spread: 0.12 (6.522%)
Open: 2.00
High: 2.01
Low: 2.00
Prev. Close: 2.04
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Wed, 30th Sep 2020 18:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Itaconix PLC - chemicals company - For 2019, pretax loss narrowed to USD1.4 million from USD10.1 million the year before, on revenue that grew by 46% to USD1.3 million from USD881,000, as a result of increased product demand, cost savings and new orders from customers in Europe.

----------

New Trend Lifestyle Group PLC - Singapore-based Feng Shui products maker - For first half of 2020, pretax loss widens to SGD1.4 million from SGD314,000 the year before, on revenue that fell by 38% to SGD1.9 million from SGD3.1 million, as retail outlets were closed due to lockdown restrictions.

----------

Immupharma PLC - pharmaceutical company - For the first half of 2020, pretax loss narrows to GBP3.1 million from GBP6.7 million the year before, on revenue that dropped to GBP62,207 from GBP77,925.

----------

Echo Energy PLC - Latin American-focused upstream oil and gas firm - For the first half of 2020, pretax loss narrows to USD5.7 million from USD7.9 million, on revenue that more than doubled to USD5.7 million from USD2.7 million, on production that came up to 390,844 barrels of oil equivalent.

----------

Goldstone Resources Ltd - Africa-focused gold resource developer - For the first half of 2020, pretax loss widens to USD292,098 from USD289,951 the year before, despite a fall in administrative expenses. During period, gained formal approval for ten-year mining lease on Akrokeri and Homase licences in Ghana.

----------

Quixant PLC - Cambridge-based technology outsourcer for gaming industry - For first half of 2020, swings to pretax loss of GBP3.0 million from profit of USD3.0 million the year before. On adjusted basis, pretax loss at USD1.4 million from profit of USD3.4 million, on revenue that declined to USD27.9 million from USD41.9 million. Looking ahead, expects return to profitable trading in second half of year.

----------

Aberdeen Standard European Logistics Income PLC - Investment trust - As at June 30, net asset value per share at EUR1.13 compared to EUR1.11 on December 31.

----------

Schroder UK Public Private Trust PLC - investment trust - As at June 30, net asset value per share fell 8.1% to 45.44 pence from 49.46p at the end of December 31.

----------

Trident Royalties PLC - London-based mining royalty firm - For the first half of 2020, pretax loss widens to USD1.1 million from USD138,844 the year before. Looking ahead, commodity markets have continued to strengthen in the third quarter, leading to a positive outlook for the rest of the year.

----------

Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - For the first half of 2020, pretax loss widens to GBP835,189 from GBP706,670 the year before due to rise in administrative costs. Keeps confident outlook due to significant progress on several development fronts, including CDX antibody research.

----------

Immotion Group PLC - immersive entertainment company headquartered in Manchester - For the first half of 2020, pretax loss remains flat at GBP2.6 million, on revenue that dropped to GBP818,000 from GBP1.3 million the year before, due to four months of trading being effectively lost to the Covid-19 lockdown.

----------

India Capital Growth Fund Ltd - investment fund - As at June 30, net asset value per share down 20% to 70.42 pence from 97.02p the same date the year before. Portfolio holds 32 investee companies, as seven holdings were sold and seven new investments were made.

----------

Chesterfield Resources PLC - copper-gold exploration and development company active in Cyprus - For the first half of 2020, pretax loss narrows to GBP257,465 from GBP303,704 the year before. Looking ahead, outlook for copper and gold is robust, as commodities rose following lockdowns.

----------

URU Metals Ltd - exploration and development - For the year to the end of March, pretax loss narrows to USD732,000 from USD2.3 million due to the absence of exceptional charges related to the impairment of group's 50% interest in the Burgersfort project and shares held in Management Resource Solutions PLC.

----------

Edenville Energy PLC - operator of the Rukwa coal project in southwest Tanzania - For 2019, pretax loss widens to GBP1.9 million from GBP1.8 million, as revenue declined to GBP233,414 from GBP337,125. The lack of capital following debt repayments in Tanzania affected the company's ability to increase production to targeted levels.

----------

ADM Energy PLC - natural resources investor with assets in Nigeria - For the first half of 2020, pretax loss widens to GBP975,000 from GBP448,000, due to no revenue being made for period, compared to GBP2.2 million the prior year. Total production from Aje field was 2,126 barrels of oil per day, down from 2,967 bopd.

----------

SEEEN PLC - London-based social media technology firm - For the first half of 2020, pretax loss widens to USD2.0 million from USD219,572 the year before on sharp rise in administrative expenses, despite generating revenue of USD3.7 million. For the third quarter, revenue improved as viewer growth accelerated.

----------

Predator Oil & Gas Holdings PLC - Jersey-based oil and gas company - For the first half of 2020, pretax loss widened to GBP784,156 from GBP512,263 the year before, as no revenue generated. Successfully executed phases one and two of Pilot Enhanced Oil Recovery onshore Trinidad using injected carbon dioxide.

----------

Solo Oil PLC - AIM-listed oil investment company - For the first half of 2020, pretax loss was GBP1.3 million, widened from GBP800,000. During period, did not proceed with acquisition of offshore Netherlands assets from ONE Dyas. Is continuing to screen acquisition opportunities.

----------

Triple Point Social Housing REIT PLC - London-based real estate investment trust - As at June 30, net asset value per share is up at 105.34 pence from 103.96p the year before. For the six month-period, annualised rental income rose to GBP28.0 million from GBP21.1 million. However, pretax profit dropped to GBP9.0 million from GBP9.9 million. Dividend per share up at 2.59 pence from 2.54p. Plans to raise GBP70 million through a placing, open offer and subscription of shares at price of 106 pence each.

----------

Open Orphan PLC - pharmaceutical services company - For the first half of 2020, pretax loss widens to GBP6.8 million from GBP1.1 million, despite generating revenue of GBP7.1 million.

----------

Provexis PLC - health food ingredient maker - For the year to the end of March, pretax loss narrows to GBP424,465 from GBP533,375, on revenue that rose by 8% to GBP347,937 from GBP322,189 the year before, through high product sales.

----------

SIMEC Atlantis Energy Ltd - London-based developer of renewable and sustainable energy projects - For the first half of 2020, pretax loss narrows to GBP6.2 million from GBP12.4 million the year before, as revenue rose sharply to GBP7.9 million from GBP2.0 million, from contributions generated by the Atlantis tidal turbine and engineering services division.

----------

Trafalgar Property Group PLC - residential homes developer based in Kent - For the year to the end of March, pretax loss narrows to GBP1.0 million from GBP2.3 million, due to a smaller writing off of assets. Revenue dipped to GBP2.0 million from GBP2.1 million, reflecting the sale of two assets, compared to five assets the prior year.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 Mar 2019 10:41

ImmuPharma Preparing For Lupuzor Drug Managed Access Programme

LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and

Read more
26 Feb 2019 12:06

ImmuPharma upbeat on product from subsidiary Ureka

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.

Read more
31 Dec 2018 12:00

ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

Read more
7 Dec 2018 11:26

ImmuPharma Progressing To Make Lupuzor Available To Patients

LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said

Read more
7 Dec 2018 08:09

Immupharma plots patient recruitment for Lupzor trials

(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

Read more
26 Sep 2018 13:55

ImmuPharma still banking on Lupuzor even after failed trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.

Read more
26 Sep 2018 12:53

Wednesday broker round-up

(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.

Read more
26 Sep 2018 12:40

ImmuPharma Interim Loss Widens On Higher Costs And Lower Revenue

LONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a

Read more
9 Sep 2018 10:59

Sunday share tips: Immupharma, PCF Bank

(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.

Read more
7 Sep 2018 11:43

ImmuPharma Inks Pact With Incanthera For Nucant Cancer Programme

LONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms

Read more
7 Sep 2018 08:10

Immupharma to make 'blockbuster' lupus treatment available

(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.

Read more
14 Jun 2018 12:02

Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment

LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading

Read more
29 May 2018 09:40

ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results

LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a

Read more
23 Mar 2018 11:17

ImmuPharma Prepares To Report Lupuzor Study Results In April

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III

Read more
25 Jan 2017 14:33

ImmuPharma trial of Lupuzor continuing smoothly

(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.